Fruzaqla (Fruquintinib) Patent Expiration, LOE Window & CMS Spending

Fruzaqla (Fruquintinib) by Takeda: FDA Orange Book core substance LOE 2035-09-07, 0 AB generics, $162.0M 2024 CMS Part D & Medicaid spend, and $25,200 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTakeda
FDA Application & PathwayN217564 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-09-07
Last Listed Patent or Exclusivity Date2035-09-07
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$162.0M
2024 Medicare Part D Spend$137.5M
2024 Medicaid Spend$24.6M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($25,200 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.